Lilly’s New Anti-Amyloid Play Hinges On Tau Bet
Redesigned Phase III Trial May Confirm Phase II Donanemab Results
TRAILBLAZER-ALZ met the primary, but not most secondary endpoints. Lilly said efficacy of its amyloid-clearing agent depends on tau levels at baseline and reductions in some parts of the brain.
You may also be interested in...
The pharma is digging deeper with early- and mid-stage R&D in age-related neurodegeneration, diabetes/obesity and other priority areas.
Lilly’s Alzheimer’s Drug Will Get ‘Easier Ride’ Than Aduhelm But Does Not Show Clinical Benefit, Prof Says
Harsh assessment of Lilly’s Phase II study by UCL and UCSF professors suggests donanemab may face same hurdles as Biogen’s Aduhelm. Lilly exec says the drug slowed disease progression by six months, but UCL prof says that won’t make a difference.
Company maintains that the upcoming Medicare national coverage policy for Alzheimer’s drugs should not impose the same access restrictions on drugs with better evidence of effectiveness than others.